본문 바로가기
KERD
논문KCI 등재

Breakthrough in heart failure with preserved ejection fraction: are we there yet?

Shir Lynn Lim|Carolyn Su Ping Lam
대한내과학회 (The Korean Association Of Internal Medicine)|2016.01|The Korean Journal of Internal Medicine|제31권 제1호|pp. 1-14|DOI http://dx.doi.org/10.3904/kjim.2016.31.1.1

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

Systemic inflammationEndothelial dysfunctionNovel therapiesHeart failure with preserved ejection fraction
주제분류내과학

초록

Heart failure with preserved ejection fraction (HFPEF) is a global health problem of considerable socioeconomic burden. It is projected to worsen with the aging population worldwide. The lack of effective therapies underscores our incomplete understanding of this complex heterogeneous syndrome. A novel paradigm has recently emerged, in which central roles are ascribed to systemic inflammation and generalized endothelial dysfunction in the pathophysiology of HFPEF. In this review, we discuss the role of the endothelium in cardiovascular homeostasis and how deranged endothelial-related signaling pathways contribute to the development of HFPEF. We also review the novel therapies in various stages of research and development that target different components of this signaling pathway.

Abstract

Heart failure with preserved ejection fraction (HFPEF) is a global health problem of considerable socioeconomic burden. It is projected to worsen with the aging population worldwide. The lack of effective therapies underscores our incomplete understanding of this complex heterogeneous syndrome. A novel paradigm has recently emerged, in which central roles are ascribed to systemic inflammation and generalized endothelial dysfunction in the pathophysiology of HFPEF. In this review, we discuss the role of the endothelium in cardiovascular homeostasis and how deranged endothelial-related signaling pathways contribute to the development of HFPEF. We also review the novel therapies in various stages of research and development that target different components of this signaling pathway.

참고문헌 (110)

  1. McMurray JJ, "ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC", Eur Heart J, 33, pp.1787~1847 (2012)
  2. Yancy CW, "2013 ACCF", AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation, J Am Coll Cardiol, pp.2013, 62[DOI]
  3. Massie BM, "Irbesartan in patients with heart failure and preserved ejection fraction", N Engl J Med, 359, pp.2456~2467 (2008)
  4. Cleland JG, "The perindopril in elderly people with chronic heart failure(PEP-CHF)study", Eur Heart J, 27, pp.2338~2345 (2006)
  5. Yusuf S, "Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial", Lancet, 362, pp.777~781 (2003)
  6. Pitt B, "Spironolactone for heart failure with preserved ejection fraction", N Engl J Med, 370, pp.1383~1392 (2014)
  7. Oktay AA, "The emerging epidemic of heart failure with preserved ejection fraction", Curr Heart Fail Rep, 10, pp.401~410 (2013)
  8. van Heerebeek L, "Myocardial structure and function differ in systolic and diastolic heart failure", Circulation, 113, pp.1966~1973 (2006)
  9. van Heerebeek L, "Low myocardial protein kinase G activity in heart failure with preserved ejection fraction", Circulation, 126, pp.830~839 (2012)
  10. Westermann D, "Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction", Circ Heart Fail, 4, pp.44~52 (2011)
  11. Borbely A, "Cardiomyocyte stiffness in diastolic heart failure", Circulation, 111, pp.774~781 (2005)
  12. Chaturvedi RR, "Passive stiffness of myocardium from congenital heart disease and implications for diastole", Circulation, 121, pp.979~988 (2010)
  13. Campbell RT, "What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?", J Am Coll Cardiol, 60, pp.2349~2356 (2012)
  14. Mohammed SF, "Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study", Circ Heart Fail, 5, pp.710~719 (2012)
  15. Paulus WJ, "A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation", J Am Coll Cardiol, 62, pp.263~271 (2013)
  16. Lim SL, "Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction", Eur Heart J, 36, pp.2050~2060 (2015)
  17. Brutsaert DL, "Cardiac endothelial-myocardial signaling:its role in cardiac growth, contractile performance, and rhythmicity", Physiol Rev, 83, pp.59~115 (2003)
  18. Castro LR, "Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes", Circulation, 113, pp.2221~2228 (2006)
  19. Takimoto E, "Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5", Circulation, 115, pp.2159~2167 (2007)
  20. Cornwell TL, "Regulation of sarcoplasmic reticulum protein phosphorylation by localized cyclic GMP-dependent protein kinase in vascular smooth muscle cells", Mol Pharmacol, 40, pp.923~931 (1991)
  21. Schlossmann J, "Regulation of intracellular calcium by a signalling complex of IRAG, IP3 receptor and cGMP kinase Ibeta", Nature, 404, pp.197~201 (2000)
  22. Bolotina VM, "Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle", Nature, 368, pp.850~853 (1994)
  23. Horowitz A, "Mechanisms of smooth muscle contraction", Physiol Rev, 76, pp.967~1003 (1996)
  24. Moncada S, "Nitric oxide: physiology, pathophysiology, and pharmacology", Pharmacol Rev, 43, pp.109~142 (1991)
  25. Radomski M, "Mechanisms of Platelet Activation and Control", pp.251~264 (1993), Plenum Press
  26. De Caterina R, "Nitric oxide decreases cytokine-induced endothelial activation: nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines", J Clin Invest, 96, pp.60~68 (1995)
  27. McNamara DB, "L-arginine inhibits balloon catheter-induced intimal hyperplasia", Biochem Biophys Res Commun, 193, pp.291~296 (1993)
  28. Mohan P, "Myocardial contractile response to nitric oxide and cGMP", Circulation, 93, pp.1223~1229 (1996)
  29. Rastaldo R, "Nitric oxide and cardiac function", Life Sci, 81, pp.779~793 (2007)
  30. Vila-Petroff MG, "Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes", Circ Res, 84, pp.1020~1031 (1999)
  31. Layland J, "Role of cyclic GMP-dependent protein kinase in the contractile response to exogenous nitric oxide in rat cardiac myocytes", J Physiol, 540(Pt 2), pp.457~467 (2002)
  32. LeWinter MM, "Cardiac titin: a multifunctional giant", Circulation, 121, pp.2137~2145 (2010)
  33. Paulus WJ, "Nitric oxide’s role in the heart:control of beating or breathing?", Am J Physiol Heart Circ Physiol, 287, pp.H8~H13 (2004)
  34. Ather S, "Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction", J Am Coll Cardiol, 59, pp.998~1005 (2012)
  35. Kalogeropoulos A, "Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study", J Am Coll Cardiol, 55, pp.2129~2137 (2010)
  36. Matsubara J, "Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction", J Am Coll Cardiol, 57, pp.861~869 (2011)
  37. Shah KB, "Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction", Clin Chem, 57, pp.874~882 (2011)
  38. Matsubara BB, "Left ventricular adaptation to chronic pressure overload induced by inhibition of nitric oxide synthase in rats", Basic Res Cardiol, 93, pp.173~181 (1998)
  39. Calderone A, "Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts", J Clin Invest, 101, pp.812~818 (1998)
  40. Giannetta E, "Chronic inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging", Circulation, 125, pp.2323~2333 (2012)
  41. Kasner M, "Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction", J Am Coll Cardiol, 57, pp.977~985 (2011)
  42. Zannad F, "Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure", Heart Fail Rev, 10, pp.71~78 (2005)
  43. Lam CS, "Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study", J Am Coll Cardiol, 53, pp.1119~1126 (2009)
  44. Farrero M, "Pulmonary hypertension is related to peripheral endothelial dysfunction in heart failure with preserved ejection fraction", Circ Heart Fail, 7, pp.791~798 (2014)
  45. Moraes DL, "Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management", Circulation, 102, pp.1718~1723 (2000)
  46. Kalk P, "NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5", 6 nephrectomy, 2006, pp.148, 853~859
  47. Boerrigter G, "Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure", Circulation, 107, pp.686~689 (2003)
  48. Borlaug BA, "Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction", J Am Coll Cardiol, 56, pp.845~854 (2010)
  49. Kitzman DW, "Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction", Am J Physiol Heart Circ Physiol, 306, pp.H1364~H1370 (2014)
  50. Mohammed SF, "Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction", Circulation, 131, pp.550~559 (2015)
  51. Akiyama E, "Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejecion fraction", J Am Coll Cardiol, 60, pp.1778~1786 (2012)
  52. Matsue Y, "Endothelial dysfunction measured by peripheral arterial tonometry predicts prognosis in patients with heart failure with preserved ejection fraction", Int J Cardiol, 168, pp.36~40 (2013)
  53. van Heerebeek L, "Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension", Circulation, 117, pp.43~51 (2008)
  54. Kawaguchi M, "A comparison of ultrastructural changes on endomyocardial biopsy specimens obtained from patients with diabetes mellitus with and without hypertension", Heart Vessels, 12, pp.267~274 (1987)
  55. Lam CS, "Diabetic cardiomyopathy: an expression of stage B heart failure with preserved ejection fraction", Diab Vasc Dis Res, 12, pp.234~238 (2015)
  56. Jonk AM, "Microvascular dysfunction in obesity:a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension", Physiology, 22, pp.252~260 (2007)
  57. Wallis MG, "Insulin-mediated hemodynamic changes are impaired in muscle of Zucker obese rats", Diabetes, 51, pp.3492~3498 (2002)
  58. Clerk LH, "Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle", Diabetes, 55, pp.1436~1442 (2006)
  59. de Jongh RT, "Impaired microvascular function in obesity:implications for obesity-associated microangiopathy, hypertension, and insulin resistance", Circulation, 109, pp.2529~2535 (2004)
  60. Steinberg HO, "Obesity", insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance, 1996, pp.97, 2601~2610
  61. De Filippis E, "Exercise-induced improvement in vasodilatory function accompanies increased insulin sensitivity in obesity and type 2 diabetes mellitus", J Clin Endocrinol Metab, 91, pp.4903~4910 (2006)
  62. McMurray JJ, "Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial", Eur J Heart Fail, 10, pp.149~156 (2008)
  63. Bhatia RS, "Outcome of heart failure with preserved ejection fraction in a population-based study", N Engl J Med, 355, pp.260~269 (2006)
  64. Fischer M, "Prevalence of left ventricular diastolic dysfunction in the community: results from a Doppler echocardiographic-based survey of a population sample", Eur Heart J, 24, pp.320~328 (2003)
  65. Melchiorre K, "Preeclampsia is associated with persistent postpartum cardiovascular impairment", Hypertension, 58, pp.709~715 (2011)
  66. Cohen RA, "Vascular oxidative stress: the common link in hypertensive and diabetic vascular disease", J Cardiovasc Pharmacol, 55, pp.308~316 (2010)
  67. Preston RA, "Effects of severe, uncontrolled hypertension on endothelial activation: soluble vascular cell adhesion molecule-1, soluble intercellular adhesion molecule-1 and von Willebrand factor", J Hypertens, 20, pp.871~877 (2002)
  68. Levy BI, "Struijker-Boudier HA. Microcirculation in hypertension: a new target for treatment?", Circulation, 104, pp.735~740 (2001)
  69. Houben AJ, "Quantitative analysis of retinal vascular changes in essential and renovascular hypertension", J Hypertens, 13(12 Pt 2), pp.1729~1733 (1995)
  70. West R, "Characterization of heart failure patients with preserved ejection fraction:a comparison between ADHERE-US registry and ADHERE-International registry", Eur J Heart Fail, 13, pp.945~952 (2011)
  71. Petrofsky JS, "CoQ10 and endothelial function in Asians from Korea compared to Asians born in the United States and US born Caucasians", Med Sci Monit, 19, pp.339~346 (2013)
  72. Shantsila E, "Ethnic differences in macrovascular and microvascular function in systolic heart failure", Circ Heart Fail, 4, pp.754~762 (2011)
  73. Katz SD, "Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure", J Am Coll Cardiol, 36, pp.845~851 (2000)
  74. Guazzi M, "PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study", Circ Heart Fail, 4, pp.8~17 (2011)
  75. Redfield MM, "Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction:a randomized clinical trial", JAMA, 309, pp.1268~1277 (2013)
  76. Blanco-Rivero J, "Participation of prostacyclin in endothelial dysfunction induced by aldosterone in normotensive and hypertensive rats", Hypertension, 46, pp.107~112 (2005)
  77. Farquharson CA, "Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy", Clin Sci, 103, pp.425~431 (2002)
  78. Virdis A, "Spironolactone improves angiotensin-induced vascular changes and oxidative stress", Hypertension, 40, pp.504~510 (2002)
  79. Sanz-Rosa D, "Eplerenone reduces oxidative stress and enhances eNOS in SHR: vascular functional and structural consequences", Antioxid Redox Signal, 7(9-10), pp.1294~1301 (2005)
  80. Farquharson CA, "Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I", angiotensin II conversion in patients with chronic heart failure, 2000, pp.101, 594~597
  81. Deswal A, "Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial(RAAM-PEF)", J Card Fail, 17, pp.634~642 (2011)
  82. Edelmann F, "Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction : the Aldo-DHF randomized controlled trial", JAMA, 309, pp.781~791 (2013)
  83. Pfeffer MA, "Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial", Circulation, 131, pp.34~42 (2015)
  84. Shah AM, "8-bromo-cGMP reduces the myofilament response to Ca2+ in intact cardiac myocytes", Circ Res, 74, pp.970~978 (1994)
  85. Paulus WJ, "Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans: assessment by bicoronary sodium nitroprusside infusion", Circulation, 89, pp.2070~2078 (1994)
  86. Cohn JN, "Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study", N Engl J Med, 314, pp.1547~1552 (1986)
  87. Taylor AL, "Combination of isosorbide dinitrate and hydralazine in blacks with heart failure", N Engl J Med, 351, pp.2049~2057 (2004)
  88. Zamani P, "Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction", Circulation, 131, pp.371~380 (2015)
  89. Evgenov OV, "NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential", Nat Rev Drug Discov, 5, pp.755~768 (2006)
  90. Jones ES, "Cardioprotective effects in aged spontaneously hypertensive rats due to chronic stimulation", activation of sGC without hypotension, 2009, pp.9(Suppl 1), P29~
  91. Masuyama H, "Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart", Hypertens Res, 32, pp.597~603 (2009)
  92. Schindler U, "Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase", Mol Pharmacol, 69, pp.1260~1268 (2006)
  93. Stasch JP, "NO-independent regulatory site on soluble guanylate cyclase", Nature, 410, pp.212~215 (2001)
  94. Bonderman D, "Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study", Chest, 146, pp.1274~1285 (2014)
  95. Gu J, "Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)", J Clin Pharmacol, 50, pp.401~414 (2010)
  96. Solomon SD, "The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial", Lancet, 380, pp.1387~1395 (2012)
  97. Liu G, "Meta-analysis of the effect of statins on mortality in patients with preserved ejection fraction", Am J Cardiol, 113, pp.1198~1204 (2014)
  98. Borbely A, "Molecular determinants of heart failure with normal left ventricular ejection fraction", Pharmacol Rep, 61, pp.139~145 (2009)
  99. Willemsen S, "The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction", Am Heart J, 164, pp.742.e3~749.e3 (2012)
  100. Little WC, "The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure", J Card Fail, 11, pp.191~195 (2005)
  101. Hornig B, "Physical training improves endothelial function in patients with chronic heart failure", Circulation, 93, pp.210~214 (1996)
  102. Edelmann F, "Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction:results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study", J Am Coll Cardiol, 58, pp.1780~1791 (2011)
  103. Kitzman DW, "Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial", Circ Heart Fail, 3, pp.659~667 (2010)
  104. Kitzman DW, "Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial", J Am Coll Cardiol, 62, pp.584~592 (2013)
  105. Heilbronn LK, "Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women", Arterioscler Thromb Vasc Biol, 21, pp.968~970 (2001)
  106. Ziccardi P, "Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year", Circulation, 105, pp.804~809 (2002)
  107. Romero-Corral A, "Modest visceral fat gain causes endothelial dysfunction in healthy humans", J Am Coll Cardiol, 56, pp.662~666 (2010)
  108. Leichman JG, "Dramatic reversal of derangements in muscle metabolism and left ventricular function after bariatric surgery", Am J Med, 121, pp.966~973 (2008)
  109. Wong CY, "Effect of weight loss due to lifestyle intervention on subclinical cardiovascular dysfunction in obesity(body mass index >30 kg", m2), 2006, pp.98, 1593~1598
  110. de las Fuentes L, "Effect of moderate diet-induced weight loss and weight regain on cardiovascular structure and function", J Am Coll Cardiol, 54, pp.2376~2381 (2009)

관련 논문AI추천

Heart failure with preserved ejection fraction: insights from recent clinical researchesMi-Na Kim, Seong-Mi Park대한내과학회 · The Korean Journal of Internal Medicine2020 · 제35권 제3호Obesity-related heart failure with preserved ejection fraction: diagnostic and therapeutic challenges정미향, Mi-Seung Shin대한내과학회 · The Korean Journal of Internal Medicine2023 · 제38권 제2호Obesity and heart failure with preserved ejection fraction: focus on new drugs and future direction in medical treatmentByung-Su Yoo, Se-Eun Kim대한내과학회 · The Korean Journal of Internal Medicine2025 · 제40권 제3호Biomarkers in Heart Failure: From Research to Clinical PracticeBerezin Alexander A., Berezin Alexander E.대한진단검사의학회 · Annals of Laboratory Medicine2023 · 제43권 제3호Blood pressure and heart failure: focused on treatmentChun Kyeong-Hyeon, Kang Seok Min대한고혈압학회 · Clinical Hypertension2024 · 제30권 Therapeutic Strategies for Diastolic Dysfunction: A Clinical Perspective하종원, Jae K. Oh한국심초음파학회 · Journal of Cardiovascular Imaging2009 · 제17권 제3호

이 간행물의 다른 논문 (25건)

Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?고원중, Wing Wai Yewpp. 15-29The antibacterial effect of fatty acids on Helicobacter pylori infection이상우, 정성우pp. 30-35Can a high-flow nasal cannula substitute for noninvasive positive pressure ventilation in post-extubation respiratory failure?김제형pp. 36-39New monoclonal antibody-based test for Helicobacter pylori urease in gastric tissueWoo Jong Kim, Hyung Rag Kim, Young Do Jung, Young Eun Joo, Jae Won Beom, Do Hyun Kim, Ho Dong Kim, Hyeuk Park, Seung Choi, Chang Kook Park, Young Jik Lee, Ju Young Park, Chul Parkpp. 40-45Feasibility of α-fetoprotein as a diagnostic tool for hepatocellular carcinoma in KoreaJoon Hyoek Lee, Dae Geon Ahn, Yong Han Paik, 배시현, 이현웅, Hyung Joon Kim, 강현, 이준성pp. 46-53
원문 보기